ReviewExperimental hematology & oncology2023
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era.
Review in Experimental hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Investigating apoptosis in peripheral blood mononuclear cells among the elderly in the post-COVID-19 era.BMC immunology · 2025Article
- SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.Annals of hematology · 2025Article
- Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights.Clinical and experimental medicine · 2024Review
- Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.Cancer medicine · 2024Review
- Identification of SARS-CoV-2-specific T cell and its receptor.Journal of hematology & oncology · 2024Article
- Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.Clinical hematology international · 2024Review
- Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study.Frontiers in oncology · 2024Article
- Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.Frontiers in oncology · 2024Article
- [Characteristics and impact factors of SARS-CoV-2 infection in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving chimeric antigen receptor T-cell therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 16 institutions in 1 country.
Funding
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and individuals will remain susceptible to recurrent infections. Chimeric antigen receptor (CAR)-T recipients are characterized by durable B-cell aplasia, hypogammaglobulinemia and loss of T-cell diversity, which lead to an increased proportion of severe/critical cases and a high mortality rate after COVID-19 infection. Thus, treatment decisions have become much more complex and require greater caution when considering CAR T-cell immunotherapy. Hence, we reviewed the current understanding of COVID-19 and reported clinical experience in the management of COVID-19 and CAR-T therapy. After a panel discussion, we proposed a rational procedure pertaining to CAR-T recipients with the aim of maximizing the benefit of CAR-T therapy in the post COVID-19 pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.